PORTRAZZA
Clinical safety rating
cautionComprehensive clinical and safety monograph for PORTRAZZA (PORTRAZZA).
Comprehensive clinical and safety monograph for PORTRAZZA (PORTRAZZA).
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
PORTRAZZA (necitumumab) is a recombinant human IgG1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
| Metabolism | Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways. |
| Excretion | Necitumumab is an IgG1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established. |
| Half-life | Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade. |
| Protein binding | Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported. |
| Volume of Distribution | Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution. |
| Bioavailability | Intravenous: 100% (not applicable to other routes). |
| Onset of Action | Intravenous: Clinical effect (e.g., EGFR inhibition) occurs within hours of first dose; however, objective tumor response may take weeks to months. |
| Duration of Action | Duration of EGFR blockade persists for approximately 2–3 weeks after a single dose, aligning with the dosing interval. Clinical duration of effect is continuous with regular dosing. |
| Molecular Weight | 145000 |
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (CrCL <30 mL/min) or end-stage renal disease. |
| Liver impairment | No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action, PORTRAZZA (necitumumab) can cause fetal harm when administered to a pregnant woman. Human IgG1 monoclonal antibodies are known to cross the placenta. Advise pregnant women of the potential risk to the fetus. |
| 2nd trimester | Human IgG1 monoclonal antibodies are known to cross the placenta; exposure during the second and third trimesters may result in fetal harm. Avoid use during pregnancy unless the benefit outweighs the risk. |
| 3rd trimester | Human IgG1 monoclonal antibodies cross the placenta; use in the third trimester may cause fetal harm. Avoid use during pregnancy, especially during the period of organogenesis and later trimesters. |
Clinical note
Comprehensive clinical and safety monograph for PORTRAZZA (PORTRAZZA).
| Placental transfer | Human IgG1 monoclonal antibodies are known to cross the placenta. As a monoclonal antibody, necitumumab is expected to be transferred across the placenta, especially during the second and third trimesters. |
| Breastfeeding | It is not known whether necitumumab is excreted in human milk or absorbed systemically after ingestion. Because many monoclonal antibodies are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, advise women to discontinue breastfeeding during treatment and for at least 3 months after the last dose. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose. |
| Fetal Monitoring | Monitor for infusion-related reactions, electrolyte abnormalities (especially hypomagnesemia, hypocalcemia, hypokalemia), and thromboembolic events. In pregnant patients, consider fetal monitoring with ultrasound to assess for growth abnormalities and oligohydramnios, as EGFR inhibition may affect fetal development. |
| Fertility Effects | No formal fertility studies have been conducted with necitumumab. Based on its mechanism (EGFR inhibition), there is a potential for impairment of female fertility due to effects on follicular development and ovulation. Male fertility may also be affected based on animal studies with EGFR inhibitors showing testicular degeneration. |
■ FDA Black Box Warning
No black box warnings.
| Serious Effects |
None
| Precautions | Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities., Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs., Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs., Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected., Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly., Infusion-related reactions; interrupt or discontinue for severe reactions., Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose., Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception. |
| Food/Dietary | No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis. |
| Clinical Pearls | PORTRAZZA (necitumumab) is a human IgG1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors. |
| Patient Advice | Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment. · Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat. · Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity. · Do not receive live vaccines while on PORTRAZZA. · Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential. |
Loading safety data…